Sonoma Pharmaceuticals Inc (SNOA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sonoma Pharmaceuticals Inc (SNOA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH13919D
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Sonoma Pharmaceuticals Inc (Sonoma), formerly Oculus Innovative Sciences, is a pharmaceutical company that develops, manufactures and markets prescription and non-prescription products for the treatment of dermatological conditions and advanced tissue care. The company offers products for advanced wound management, nursing home and home healthcare, wound and skin care, among others. It offers women's healthcare products, Microcyn skin and wound care products, Regenacyn advanced scar management hydrogel and animal healthcare, among others. Sonoma develops its products based on shelf-stable microcyn technology platform. The company sells its products through OTC stores. The company operates in the Netherlands and the US. Sonoma is headquartered in Petaluma, California, the US.

Sonoma Pharmaceuticals Inc (SNOA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13

Licensing Agreements 13

Brill Pharma Enters into Licensing Agreement with Sonoma Pharma 13

U.SK Dermatology Enters into Licensing Agreement with Sonoma Pharma 14

Oculus Innovative Amends the Licensing Agreement With Ruthigen 15

AmDerma Pharma Exercises its Option Licensing Agreement With Oculus Innovative Sciences 17

Oculus Innovative Sciences Enters Into Licensing Agreement With More Pharma 18

Equity Offering 19

Sonoma Pharma Prices Public Offering of Units 19

Sonoma Pharma Raises USD5 Million in Public Offering of Shares 20

Oculus Innovative Sciences Raises USD3.26 million in Public Offering Of Shares 22

Oculus Innovative Sciences Raises USD3.4 Million in Public Offering of Units 23

Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 24

Oculus Innovative Sciences Raises USD6.3 Million in Public Offering of Shares and Warrants 25

Oculus Innovative Sciences Raises USD1.35 Million in Private Placement Of Units 27

Oculus Innovative Sciences Completes Private Placement Of Shares For USD 2.2 Million 28

Oculus Innovative Sciences Completes Public Offering Of Common Stock For USD 3.5 Million 29

Oculus Innovative Sciences Completes Private Placement Of Preferred Stock For USD 1 Million 30

Oculus Innovative Sciences Completes Private Placement Of Shares For USD 2 Million 31

Asset Transactions 32

Invekra Acquires Latin America Business of Sonoma Pharma for USD22 Million 32

Sonoma Pharmaceuticals Inc-Key Competitors 33

Sonoma Pharmaceuticals Inc-Key Employees 34

Sonoma Pharmaceuticals Inc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Business Unit 36

Recent Developments 37

Financial Announcements 37

Nov 08, 2018: Sonoma Pharmaceuticals reports record revenue in second quarter FY 2019 37

Aug 08, 2018: Sonoma Pharmaceuticals reports first quarter fy 2019 financial results 39

Jun 13, 2018: Sonoma Pharmaceuticals Announces Fiscal Year And Fourth Quarter 2018 Financial Results 40

Feb 07, 2018: Sonoma Pharmaceuticals Reports Record Total Revenue of USD 4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% 42

Nov 09, 2017: Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of USD 4.3 Million 44

Aug 08, 2017: Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 46

Feb 09, 2017: Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017 47

Corporate Communications 49

Sep 19, 2018: Sonoma Pharmaceuticals names Phillipe Weigerstorfer as Board Director 49

May 08, 2018: Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer 50

Jan 31, 2017: Sonoma Pharmaceuticals Appoints Marc Umscheid As Chief Strategy And Marketing Officer 51

Other Significant Developments 52

Aug 28, 2018: Sonoma Pharmaceuticals announces results from study of sonoma's performance-stabilized HOCl (hypochlorous acid) in management of acne vulgaris 52

Jul 13, 2017: Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sonoma Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Sonoma Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Sonoma Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Brill Pharma Enters into Licensing Agreement with Sonoma Pharma 13

U.SK Dermatology Enters into Licensing Agreement with Sonoma Pharma 14

Oculus Innovative Amends the Licensing Agreement With Ruthigen 15

AmDerma Pharma Exercises its Option Licensing Agreement With Oculus Innovative Sciences 17

Oculus Innovative Sciences Enters Into Licensing Agreement With More Pharma 18

Sonoma Pharma Prices Public Offering of Units 19

Sonoma Pharma Raises USD5 Million in Public Offering of Shares 20

Oculus Innovative Sciences Raises USD3.26 million in Public Offering Of Shares 22

Oculus Innovative Sciences Raises USD3.4 Million in Public Offering of Units 23

Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 24

Oculus Innovative Sciences Raises USD6.3 Million in Public Offering of Shares and Warrants 25

Oculus Innovative Sciences Raises USD1.35 Million in Private Placement Of Units 27

Oculus Innovative Sciences Completes Private Placement Of Shares For USD 2.2 Million 28

Oculus Innovative Sciences Completes Public Offering Of Common Stock For USD 3.5 Million 29

Oculus Innovative Sciences Completes Private Placement Of Preferred Stock For USD 1 Million 30

Oculus Innovative Sciences Completes Private Placement Of Shares For USD 2 Million 31

Invekra Acquires Latin America Business of Sonoma Pharma for USD22 Million 32

Sonoma Pharmaceuticals Inc, Key Competitors 33

Sonoma Pharmaceuticals Inc, Key Employees 34

Sonoma Pharmaceuticals Inc, Other Locations 35

Sonoma Pharmaceuticals Inc, Subsidiaries 35

Sonoma Pharmaceuticals Inc, Business Unit 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Sonoma Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17810
Site License
USD 500 INR 35620
Corporate User License
USD 750 INR 53430

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com